TG Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.4 Mil. TG Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $109.3 Mil. TG Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $160.5 Mil.
TG Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.69.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TG Therapeutics's Debt-to-Equity or its related term are showing as below:
TGTX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.08 Max: 1.42
Current: 0.69
During the past 13 years, the highest Debt-to-Equity Ratio of TG Therapeutics was 1.42. The lowest was 0.00. And the median was 0.08.
TG Therapeutics Debt-to-Equity Historical Data
The historical data trend for TG Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
TG Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
1.06 |
0.08 |
0.33 |
1.42 |
0.69 |
|
TG Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.42 |
3.94 |
2.70 |
0.07 |
0.69 |
Competitive Comparison
For the Biotechnology subindustry, TG Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, TG Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's Debt-to-Equity falls into.
TG Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
TG Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
TG Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics (TG Therapeutics) Business Description
Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
| Laurence N Charney |
director |
MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016 |
| Sean A Power |
officer: CFO, Secretary and Treasurer |
787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019 |
| Michael S Weiss |
director, officer: CEO and President |
750 LEXINGTON AVE, NEW YORK NY 10022 |
| Sagar Lonial |
director |
C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014 |
| Yann Echelard |
director |
C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958 |
| Ra Capital Management, L.p. |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Kenneth Hoberman |
director |
750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024 |
| Daniel Hume |
director |
3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
| William James Kennedy |
director |
C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989 |
| Ra Capital Healthcare Fund Lp |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Rajeev M. Shah |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Peter Kolchinsky |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Lfb Biotechnologies S.a.s.u. |
10 percent owner |
3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958 |
| Mark Schoenebaum |
director |
787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019 |
| Opus Point Partners, Llc |
10 percent owner |
787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019 |
TG Therapeutics (TG Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TGTX has been successfully added to your